PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
25 01 2021
Historique:
received: 24 07 2020
accepted: 09 12 2020
pubmed: 18 12 2020
medline: 5 6 2021
entrez: 17 12 2020
Statut: epublish

Résumé

Tumor antigen-specific CD4 T cells accumulate at tumor sites, evoking their involvement in antitumor effector functions in situ. Contrary to CD8 cytotoxic T lymphocyte exhaustion, that of CD4 T cells remains poorly appreciated. Here, using phenotypic, transcriptomic, and functional approaches, we characterized CD4 T cell exhaustion in patients with head and neck, cervical, and ovarian cancer. We identified a CD4 tumor-infiltrating lymphocyte (TIL) population, defined by high PD-1 and CD39 expression, which contained high proportions of cytokine-producing cells, although the quantity of cytokines produced by these cells was low, evoking an exhausted state. Terminal exhaustion of CD4 TILs was instated regardless of TIM-3 expression, suggesting divergence with CD8 T cell exhaustion. scRNA-Seq and further phenotypic analyses uncovered similarities with the CD8 T cell exhaustion program. In particular, PD-1hiCD39+ CD4 TILs expressed the exhaustion transcription factor TOX and the chemokine CXCL13 and were tumor antigen specific. In vitro, PD-1 blockade enhanced CD4 TIL activation, as evidenced by increased CD154 expression and cytokine secretion, leading to improved dendritic cell maturation and consequently higher tumor-specific CD8 T cell proliferation. Our data identify exhausted CD4 TILs as players in responsiveness to immune checkpoint blockade.

Identifiants

pubmed: 33332284
pii: 142513
doi: 10.1172/jci.insight.142513
pmc: PMC7934837
doi:
pii:

Substances chimiques

Antigens, Neoplasm 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0
RNA, Messenger 0
Apyrase EC 3.6.1.5
ENTPD1 protein, human EC 3.6.1.5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
Nat Methods. 2017 Sep;14(9):865-868
pubmed: 28759029
Cancer Res. 2012 Mar 1;72(5):1059-63
pubmed: 22253231
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Cancer Immunol Res. 2013 Nov;1(5):303-8
pubmed: 24777968
J Exp Med. 2017 Jun 5;214(6):1567-1580
pubmed: 28526759
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
Immunity. 2018 May 15;48(5):1029-1045.e5
pubmed: 29768164
J Clin Invest. 2004 Apr;113(8):1225-33
pubmed: 15085202
BMC Genomics. 2018 Jun 19;19(1):477
pubmed: 29914354
Nature. 2019 Jul;571(7764):270-274
pubmed: 31207604
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Nucleic Acids Res. 2019 Dec 2;47(21):e133
pubmed: 31294801
Nature. 2019 Jul;571(7764):265-269
pubmed: 31207605
Nat Biotechnol. 2019 May;37(5):547-554
pubmed: 30936559
Nat Immunol. 2013 Dec;14(12):1285-93
pubmed: 24162775
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Cancer Immunol Res. 2020 Jul;8(7):869-882
pubmed: 32295784
Cancer Immunol Res. 2019 May;7(5):784-796
pubmed: 30872264
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
Cancer Res. 2018 Jul 1;78(13):3604-3618
pubmed: 29559470
Cell Rep. 2019 May 21;27(8):2411-2425.e9
pubmed: 31116985
Nat Commun. 2018 Sep 19;9(1):3762
pubmed: 30232328
J Immunol. 2015 Apr 1;194(7):3475-86
pubmed: 25725111
NAR Genom Bioinform. 2020 Apr 20;2(2):lqaa025
pubmed: 33575582
Cancer Immunol Res. 2020 Oct;8(10):1311-1321
pubmed: 32759363
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
Cancer Immunol Res. 2014 Feb;2(2):91-8
pubmed: 24778273
Nature. 2019 Oct;574(7780):696-701
pubmed: 31645760
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023

Auteurs

Camille-Charlotte Balança (CC)

Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.

Anna Salvioni (A)

Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.

Clara-Maria Scarlata (CM)

Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
Immune Monitoring Core Facility.

Marie Michelas (M)

Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.

Carlos Martinez-Gomez (C)

Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
Department of Surgery, and.

Carlos Gomez-Roca (C)

Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.

Victor Sarradin (V)

Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.

Marie Tosolini (M)

Technological Pole and Bioinformatic Platform, Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.

Carine Valle (C)

Technological Pole and Bioinformatic Platform, Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.

Frédéric Pont (F)

Technological Pole and Bioinformatic Platform, Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.

Gwénaël Ferron (G)

Department of Surgery, and.

Laurence Gladieff (L)

Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.

Sébastien Vergez (S)

Department of Surgery, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
Université Toulouse III Paul Sabatier, Toulouse, France.

Agnès Dupret-Bories (A)

Department of Surgery, and.

Eliane Mery (E)

Department of Pathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.

Philippe Rochaix (P)

Department of Pathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.

Jean-Jacques Fournié (JJ)

Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.

Jean-Pierre Delord (JP)

Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
Université Toulouse III Paul Sabatier, Toulouse, France.

Christel Devaud (C)

Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.

Alejandra Martinez (A)

Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
Department of Surgery, and.

Maha Ayyoub (M)

Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
Immune Monitoring Core Facility.
Université Toulouse III Paul Sabatier, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH